News | Magnetic Resonance Imaging (MRI) | December 29, 2015

Novel MRI Imaging Agent More Effectively Monitors Impact of Treatment in Lung, Prostate Cancers

Novel MRI Imaging Agent More Effectively Monitors Impact of Treatment in Lung, Prostate Cancers

Molecular imaging of the GRPR biomarker on mice xenografted with PC3 and H441 cells by T1-weighted spin echo MR imaging and NIR imaging.

December 29, 2015 — A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed with a new magnetic resonance imaging (MRI) imaging agent (Scientific Reports. doi:10.1038/srep16214).

The researchers developed a new imaging agent they named ProCA1.GRPR, and demonstrated that it leads to strong tumor penetration and is capable of targeting the gastrin-releasing peptide receptor expressed on the surface of diseased cells, including prostate, cervical and lung cancer cells.

Molecular imaging of cancer predictors using MRI offers better and improved understanding of various cancers and drug activity during preclinical and clinical treatments. However, one of the major barriers in using MRI in evaluating specific disease predictors for diagnosis and monitoring drug effects is the lack of highly sensitive and specific imaging agents capable of showing the difference between normal tissue and tumors.

"ProCA1.GRPR has a strong clinical translation for human application and represents a major step forward in the quantitative imaging of disease biomarkers without the use of radiation," said lead author Jenny J. Yang, Ph.D., professor and associate director of the Center for Diagnostics and Therapeutics at Georgia State University in Atlanta. "This information is valuable for staging disease progression and monitoring treatment effects."

The researchers' results are an important advancement for molecular imaging. This agent has a unique ability to quantitatively detect expression level and spatial distribution of disease predictors without using radiation.

"Our discovery is of great interest to both chemists and clinicians for disease diagnosis, including noninvasive early detection of human diseases, cancer biology, molecular basis of human diseases, and translational research with preclinical and clinical applications," said coauthor Shenghui Xue, Ph.D., postdoctoral researcher in Georgia State Department of Chemistry.

Improved imaging agents such as ProCA1.GRPR have implications in understanding disease development and treatment.

For more information: www.nature.com/articles/srep16214

Related Content

Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
Fans of Opposing Soccer Teams Perceive Games Differently

Image courtesy of University of York

News | Neuro Imaging | October 25, 2018
Scientists have scanned the brains of die-hard soccer fans to find out why supporters of rival teams often have very...
IMRIS, Siemens Strengthen Collaboration in Hybrid OR Neurosurgical Market
News | Hybrid OR | October 24, 2018
IMRIS, Deerfield Imaging, in partnership with Siemens Healthineers, announced a strengthened collaboration to advance...
Carotid Artery MRI Improves Cardiovascular Disease Risk Assessment
News | Magnetic Resonance Imaging (MRI) | October 23, 2018
Magnetic resonance imaging (MRI) measurements of wall thickness in the carotid arteries improve cardiovascular disease...
The Elekta Unity with 1.5T MRI embedded as a targeting system appeared at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas. The system is being sold in Europe and could soon enter the U.S. marketplace. (Photo courtesy of Elekta)

The Elekta Unity with 1.5T MRI embedded as a targeting system appeared at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas. The system is being sold in Europe and could soon enter the U.S. marketplace. (Photo courtesy of Elekta)

Feature | ASTRO | October 20, 2018 | By Greg Freiherr
A linear accelerator combined with high-field MRI could soon be on the U.S. market. If U.S.
FDA Clears Magnetom Sola 1.5T MRI From Siemens Healthineers
Technology | Magnetic Resonance Imaging (MRI) | October 09, 2018
The U.S. Food and Drug Administration (FDA) has cleared the Magnetom Sola, a 1.5 Tesla magnetic resonance imaging (MRI...